Pharmacotherapy for Compulsive Personality

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Compulsive Personality+2 More
Pharmacotherapy - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is for OCD patients who have completed a different study protocol and are now looking for aftercare treatment options.

Eligible Conditions
  • Compulsive Personality
  • Obsessive-Compulsive Disorder

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Compulsive Personality

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Up to 14 weeks

Up to 14 weeks
Improvement in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

Trial Safety

Safety Progress

1 of 3

Other trials for Compulsive Personality

Trial Design

2 Treatment Groups

Pharmacotherapy
1 of 2
Psychotherapy
1 of 2
Active Control

200 Total Participants · 2 Treatment Groups

Primary Treatment: Pharmacotherapy · No Placebo Group · N/A

Pharmacotherapy
Other
ActiveComparator Group · 1 Intervention: Pharmacotherapy · Intervention Types: Other
Psychotherapy
Behavioral
ActiveComparator Group · 1 Intervention: Psychotherapy · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 14 weeks

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,148 Previous Clinical Trials
35,678,968 Total Patients Enrolled
Carolyn Rodriguez, MD, PhDPrincipal Investigator - Assistant Professor, Stanford University
Stanford University
3 Previous Clinical Trials
16 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: October 13th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.